Articles tagged with Thyroid Cancer
The Journal of Nuclear Medicine Technology special issue highlights the potential of theranostics to tailor cancer treatment to individual patients. The innovation uses targeted radiopharmaceuticals for both diagnosis and treatment of tumors.
A study found that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells. Inhibition of EGFR by lapatinib therapy in combination with lenvatinib enhanced growth inhibitory effect and inhibited tumor growth more remarkably than monotherapy.
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
A study examining the link between pesticide exposure and thyroid cancer risk found that 10 out of 29 reviewed pesticides were associated with an increased risk. Exposure to paraquat dichloride was consistently linked to thyroid cancer, while higher numbers of pesticides over a 20-year period proportionally increased risk.
The study found an overall response rate of 57% and disease control rate of 83% in 23 patients with diverse cancer types. These results validate RET as a tissue-agnostic target with sensitivity to RET inhibition.
A new study estimates that exposure to PFAS chemicals may result in $5.5-63 billion in lifetime health costs due to conditions like low birth weight, childhood obesity, kidney cancer, and hypothyroidism. The study supports the EPA's decision to lower safe allowable levels of these substances.
A study of 1,300 patients found most thyroid cancers are discovered in asymptomatic individuals, supporting the hypothesis of ongoing subclinical disease detection. The findings contradict the notion of a rising incidence of thyroid cancer.
Researchers developed an AI model to analyze thyroid ultrasound images, identifying nodules unlikely to be cancerous with a sensitivity of 97%. This technology could reduce the number of unnecessary biopsies and assist radiologists in choosing which nodules should undergo biopsy.
A recent study in JAMA Otolaryngology–Head & Neck Surgery reveals that thyroid cancer patients in the US experience substantial financial burdens. The researchers propose a novel framework to help guide future research and inform cancer care providers on cost considerations.
A new study from University of Gothenburg found that men with high childhood BMI are at an elevated risk of obesity-related cancer, even if their weight is normal in young adulthood. The study analyzed data from 6,565 men born between 1945 and 1961 and found a persistently increased risk of adult obesity-related cancer.
A new AI model combines multiple machine learning methods to accurately detect thyroid cancer and predict treatment outcomes from routine ultrasound images. The multimodal platform achieved high accuracy rates in detecting malignancies and predicting pathological stage and genomic mutations.
A study of 362 children found no association between increased body weight and the risk of thyroid cancer. The research evaluated these children who had been diagnosed with thyroid nodules.
Researchers at Children's Hospital of Philadelphia define a 3-tiered molecular classification system for pediatric differentiated thyroid cancer, where fusion oncogenes are associated with more invasive disease and lower remission rates. The study contrasts findings from adults, who have a two-tiered system based on BRAF mutations.
Researchers at the Paul Scherrer Institute have discovered a combination of rapamycin and a radiopharmaceutical that can effectively inhibit tumour growth, improving treatment outcomes for medullary thyroid cancer. The new therapy uses mini-gastrin coupled with lutetium-177 to target cancer cells more efficiently.
A study by University of New South Wales has found that one in five future thyroid cancers in Australia is attributable to current levels of overweight and obesity. The prevalence of obesity has doubled in the last two decades, with 75% of Australian men and 60% of women being overweight or obese.
A team at Osaka University has initiated the world's first in-human investigator-initiated clinical trial of sodium astatine ([ <sup> 211 </sup> At]NaAt) injection for refractory differentiated thyroid cancer patients. The phase I trial evaluates safety, pharmacokinetics, and efficacy of astatine for use in alpha therapy.
Firefighters who worked at the World Trade Center site after 9/11 are 13% more likely to develop cancer, particularly prostate and thyroid cancer. They were also diagnosed at a younger age, on average, with early-stage disease. The exact cause of this increased risk is unclear.
Researchers have developed a non-invasive method to diagnose thyroid cancer using photoacoustic and ultrasound image technology combined with artificial intelligence. The technique accurately classifies malignant nodules with high sensitivity and specificity, reducing unnecessary biopsies and medical costs.
The joint statement aims to address current controversies and evolving concepts in thyroid cancer care. Key findings include the use of molecular theranostics for refining management recommendations and indicators of response to RAI therapy. The statement was led by Seza Gulec, MD, and published in the peer-reviewed journal Thyroid.
Dr. Anna M. Sawka, a renowned Clinician Scientist and Endocrinologist, has been appointed the next Editor-in-Chief of Thyroid, the Official Journal of the American Thyroid Association. She will lead the journal in advancing scientific publication in the field of Thyroidology.
Research found that Filipino-Americans are more likely to be diagnosed with advanced thyroid cancer, while European Americans tend to have early-stage disease. DBP expression was also linked to cancer staging in both groups, suggesting a protective role for the protein.
Researchers found that pralsetinib achieved an overall response rate of 70% and complete response rate of 11% in patients with no prior systemic treatment for advanced RET fusion-positive NSCLC. In the thyroid arm, the ORR was 71% in patients with treatment-naïve RET-mutant medullary thyroid cancer.
A recent study has revealed a wide range of cost variations and transparency levels in the treatment of thyroid cancer. The research, conducted by Brigham and Women's Hospital, found that only half of the cancer centers studied reported payer-negotiated prices for services, with some costs varying by up to 70-fold across institutions.
The LUCA device, a low-cost near-infrared optical device combined with ultrasound, has shown potential in identifying benign or malignant thyroid nodules. Clinical tests demonstrated a 100% sensitivity and 77% specificity in classifying nodules as clear cases or those requiring further diagnosis.
Geisinger Health System has been awarded a $3.6 million contract from the National Cancer Institute to analyze genetic data from its MyCode Community Health Initiative. The study aims to identify specific gene variants linked to cancer risk, expanding the list of genes used for genetic cancer screening.
Researchers used genomic tools to investigate health effects of Chernobyl radiation, finding no evidence of genetic changes passed from parents to children. The studies identified genetic changes in thyroid cancer tumors of people exposed as children or fetuses to radiation released by the accident.
A study published in CANCER found an association between higher levels of nighttime artificial light and a 55% elevated risk of developing thyroid cancer. The association was strongest in women for localized cancer, while stronger in men for more advanced stages.
A recent study by prof. Tone Bjørge and her team reveals a strong link between in-utero exposures and an increased risk of thyroid cancer later in life. Maternal hypothyroidism, hyperthyroidism, goiter, and benign thyroid neoplasms are associated with higher risk.
A study by researchers at Dartmouth's Geisel School of Medicine found that active surveillance can be successfully implemented in patients with low-risk thyroid cancer. The study shows that 91% of patients adhered to the prescribed ultrasonography schedule and retention rates were high, with only 4.5% choosing surgery after two years.
The Phase I/II LIBRETTO-001 trial found that selpercatinib achieved durable objective responses in the majority of participants with RET gene fusions, including an ORR of 85% in previously untreated patients. The study also showed promising results in patients with brain metastases and thyroid cancers.
A majority of patients with medullary thyroid cancer treated with selpercatinib lived for more than a year without disease progression. The drug showed high efficacy and good tolerability, with response rates of up to 79% and manageable side effects.
Researchers found that up to one-third of physicians ordered thyroid ultrasounds without a clear reason supported by clinical guidelines. The study suggests clearer guidelines could help reduce low-risk thyroid cancer cases.
The global burden of thyroid cancer has increased significantly between 1990 and 2017, with a notable rise in younger age groups. The study found that the incidence rate varied greatly across different regions and socioeconomic factors, highlighting the need for targeted prevention and treatment strategies.
KinaRx aims to create more effective drugs using a novel platform that targets gene mutations driving cancer growth. The company has developed novel RET inhibitors with promising results in preclinical experiments.
Rates of thyroid cancer among World Trade Center rescue/recovery workers are significantly higher than those in the general population. Asymptomatic cancers detected during heightened medical surveillance contribute to these elevated rates.
A new study found that cancer treatment with immune checkpoint inhibitors is associated with an increased risk of thyroid dysfunction, affecting up to 40% of patients. The type of cancer and specific combination of medications used can impact the likelihood of developing thyroid problems.
A study found that physicians use varying strategies to address patients' worry about thyroid cancer, with some telling them it's a 'good cancer.' However, this approach may not be effective in alleviating worry. The research emphasizes the need for physician education and intervention to better support patients.
A study of 30,180 patients with papillary thyroid microcarcinoma found that nearly 20% had pathological signs of aggressive disease, increasing the risk of distant metastasis. The research emphasizes the need for new preoperative tests to identify high-risk tumors and thorough patient counseling on all treatment options.
The American Association of Endocrine Surgeons has published comprehensive clinical guidelines for surgical treatment of thyroid disease in adults. The guidelines emphasize personalized, evidence-based care and focus on optimizing patient outcomes.
Dr. Neal Barnard shares how common conditions like infertility, weight gain, and menopausal symptoms are fueled by hormone imbalances linked to food choices. He offers practical tips and recipes to balance hormones and improve overall health.
A new Yale School of Public Health study found that genetic variations in specific genes are associated with increased thyroid cancer risk among cell phone users. Researchers analyzed over 900 people and identified 10 SNPs that appear to increase the risk of thyroid cancer.
Researchers found an elevated overall cancer incidence among World Trade Center responders, especially in thyroid and prostate cancers. Leukemia is also reported for the first time, likely due to low-level benzene fuel exposure.
Thyroid cancer rates in the US have stabilized since 2014, with a decline in new cases per 100,000 people from 14.7 to 14.1 between 2009 and 2016. The rise in thyroid cancer was largely due to increased screening and imaging over the past three decades.
Recent study suggests a modest association between radioiodine treatment for hyperthyroidism and increased risk of solid cancer, including breast cancer. The Society for Endocrinology and British Thyroid Association advise caution in interpreting the findings and highlight the need for further research.
Researchers discovered a rare gene mutation in the DUOX2 gene associated with familial thyroid cancer, which increases the risk of hereditary non-medullary thyroid cancer. The mutated protein produces excess hydrogen peroxide, potentially causing additional genetic mutations and increasing cancer risk.
A new study found exposure to CT scans is associated with higher risks of developing thyroid cancer and leukemia. The risk is stronger in patients who have received multiple scans, particularly younger adults and females.
A U-M study found that maximizer patients consume more health care resources without clear evidence of improved outcomes. Strong maximizers had four or more doctor visits, two or more ultrasounds, and one or more radioactive iodine scans in the prior year.
Researchers developed a new metabolic thyroid test that is faster and more accurate than current diagnostic tests. The test uses mass spectrometry imaging to identify diagnostic fingerprints produced by cancerous cells, preventing thousands of unnecessary surgeries each year.
A new study reveals a shift in obesity-associated cancers towards younger individuals, with significant increases in certain types of cancers among non-Hispanic Black and Hispanic women and men. The study found that the number of cases of these cancers increased by 25% to 400% in specific populations between 2000 and 2016.
Researchers developed the MasSpec Pen to rapidly identify tissue molecular profiles for predictive diagnoses. The device uses machine learning algorithms and is being tested on human patients, showing promising results.
Researchers used Raman spectroscopy to differentiate between benign and cancerous thyroid cells, achieving 97 percent accuracy. The non-invasive technique could reduce the need for invasive procedures, minimizing surgical complications and healthcare costs.
A method developed by Brazilian and US researchers confirms a three-fold increase in thyroid cancer incidence among WTC responders compared to the general population. The four-biomarker panel distinguishes between malignant and benign tumors with no false positive results, enabling early detection and treatment.
A study led by Dr. Alliric Willis found that over 25% of low-risk thyroid cancer patients receive unnecessary radioactive iodine ablation treatment, carrying potential long-term risks and financial burdens. Younger patients, men, Hispanic, and Asian individuals are more at risk of overtreatment.
The guidelines present key areas for research, including biomarkers of thyroid action in cardiovascular tissues and clinical trials involving thyroid medications. The connection between thyroid and cardiac function has been identified as a crucial area for further investigation.
Researchers at Osaka University have developed a therapeutic drug that emits highly effective alpha rays to treat refractory thyroid cancer. The study showed promising results, with mice surviving nearly three times longer and tumors shrinking by several-fold after treatment.
A study of 872 young adults found that 14.4% borrowed over $10,000 due to illness or treatment, while 54% experienced mental task impairment. Cancer treatment with chemotherapy increased the risk of these issues significantly.
A new retrospective study shows that thyroid surgery readmissions are highest within a week of the procedure, with patients experiencing severe symptoms such as tremors and muscle spasms being most at risk. The study identifies risk factors that can be addressed to prevent these readmissions, including timely follow-up using telehealth.
A genetic test called ThyroSeq has been shown to reliably distinguish between benign and cancerous thyroid nodules using a small sample of cells. The test correctly identified cancerous nodules as positive 94% of the time and detected benign nodules as negative 82% of the time, preventing unnecessary diagnostic surgeries.
The HiLo trial found no significant difference in recurrence rates between patients given a low radiation dose compared to the standard higher dose. This means patients with low-risk thyroid cancer can benefit from fewer side effects, long-term complications, and more convenient treatment options.
A recent study published online demonstrated that Droplet Digital PCR technology can detect and quantify rare mutations in the TERT promoter region with high sensitivity. The assays detected the mutation in 78% of samples and yielded no false positives, showing its potential as a biomarker for diagnosing and monitoring patients.